{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-tumor+B&page=15", "query": { "intervention": "Anti-tumor B", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 665, "total_pages": 67, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-tumor+B&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-tumor+B&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T13:26:27.818Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02143466", "title": "AZD9291 in Combination With Ascending Doses of Novel Therapeutics", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Part A - AZD9291 in combination with AZD6094", "type": "DRUG" }, { "name": "Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)", "type": "DRUG" }, { "name": "Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)", "type": "DRUG" }, { "name": "Part A - AZD9291 in combination with intermittent selumetinib", "type": "DRUG" }, { "name": "Part A - AZD9291 in combination with MEDI4736", "type": "DRUG" }, { "name": "Part B - AZD9291 in combination with AZD6094", "type": "DRUG" }, { "name": "Part B - AZD9291 in combination with selumetinib", "type": "DRUG" }, { "name": "Part B - AZD9291 in combination with MEDI4736", "type": "DRUG" }, { "name": "Part C - AZD6094 monotherapy (Japan only)", "type": "DRUG" }, { "name": "Part C - AZD9291 in combination with AZD6094 (Japan only)", "type": "DRUG" }, { "name": "Part D - AZD9291 in combination with AZD6094", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 344, "start_date": "2014-08-05", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-15T13:26:27.818Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02143466" }, { "nct_id": "NCT05242822", "title": "A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Intrahepatic Cholangiocarcinoma", "Urothelial Carcinoma" ], "interventions": [ { "name": "KIN-3248", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kinnate Biopharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2022-03-29", "completion_date": "2024-10-03", "has_results": false, "last_update_posted_date": "2025-05-07", "last_synced_at": "2026-10-15T13:26:27.818Z", "location_count": 12, "location_summary": "Phoenix, Arizona • La Jolla, California • Jacksonville, Florida + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05242822" }, { "nct_id": "NCT01532089", "title": "Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "EGFR Exon 19 Deletion Mutation", "EGFR NP_005219.2:p.L858R", "Lung Non-Squamous Non-Small Cell Carcinoma", "Stage IV Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2012-03-16", "completion_date": "2020-08-18", "has_results": true, "last_update_posted_date": "2020-10-06", "last_synced_at": "2026-10-15T13:26:27.818Z", "location_count": 19, "location_summary": "La Jolla, California • Decatur, Illinois • Peoria, Illinois + 16 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01532089" }, { "nct_id": "NCT03424603", "title": "Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-cell Lymphoma", "Non Hodgkin Lymphoma", "Multiple Myeloma", "Follicular Lymphoma", "Mantle Cell Lymphoma", "Diffuse Large B Cell Lymphoma", "Indolent Lymphoma", "B Cells--Tumors" ], "interventions": [ { "name": "STRO-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sutro Biopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2018-02-22", "completion_date": "2024-03-15", "has_results": false, "last_update_posted_date": "2024-06-11", "last_synced_at": "2026-10-15T13:26:27.818Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Duarte, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03424603" }, { "nct_id": "NCT01281254", "title": "AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "AMG386 plus PLD", "type": "DRUG" }, { "name": "Placebo plus PLD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 223, "start_date": "2011-04-18", "completion_date": "2017-04-19", "has_results": false, "last_update_posted_date": "2017-12-02", "last_synced_at": "2026-10-15T13:26:27.818Z", "location_count": 21, "location_summary": "Los Angeles, California • San Francisco, California • Norwalk, Connecticut + 18 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01281254" }, { "nct_id": "NCT04186520", "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Hodgkin Lymphoma (NHL)", "Mantle Cell Lymphoma (MCL)", "Chronic Lymphocytic Leukemia (CLL)", "Follicular Lymphoma", "Marginal Zone Lymphoma", "Diffuse Large B Cell Lymphoma", "Primary Mediastinal Large B-cell Lymphoma (PMBCL)", "Central Nervous System Lymphoma" ], "interventions": [ { "name": "8/12-Day Production of Car-T Cells", "type": "BIOLOGICAL" }, { "name": "8/12-Day Production of Cryopreserved Car-T Cells", "type": "BIOLOGICAL" }, { "name": "12-Day Production of Car-T Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 100, "start_date": "2020-05-18", "completion_date": "2029-02-28", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-10-15T13:26:27.818Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04186520" }, { "nct_id": "NCT06422520", "title": "A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "BGB-C354", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2024-07-08", "completion_date": "2026-05-15", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-10-15T13:26:27.818Z", "location_count": 5, "location_summary": "Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 2 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06422520" }, { "nct_id": "NCT00004086", "title": "Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "indium In 111 LL2 IgG", "type": "RADIATION" }, { "name": "yttrium Y 90 epratuzumab", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Garden State Cancer Center at the Center for Molecular Medicine and Immunology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1997-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2009-06-09", "last_synced_at": "2026-10-15T13:26:27.818Z", "location_count": 1, "location_summary": "Belleville, New Jersey", "locations": [ { "city": "Belleville", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004086" }, { "nct_id": "NCT02635672", "title": "Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "VIP152 (BAY 1251152)", "type": "DRUG" }, { "name": "VIP152 (BAY 1251152) 30 mg", "type": "DRUG" }, { "name": "Keytruda", "type": "DRUG" }, { "name": "VIP152 (BAY 1251152) 15 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vincerx Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2016-02-10", "completion_date": "2024-11-11", "has_results": false, "last_update_posted_date": "2024-11-15", "last_synced_at": "2026-10-15T13:26:27.818Z", "location_count": 13, "location_summary": "Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Silver Spring", "state": "Maryland" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02635672" }, { "nct_id": "NCT03819465", "title": "A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Non-Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Danvatirsen", "type": "DRUG" }, { "name": "Oleclumab", "type": "DRUG" }, { "name": "MEDI5752", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "AZD2936", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 175, "start_date": "2018-12-27", "completion_date": "2026-07-01", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-10-15T13:26:27.818Z", "location_count": 3, "location_summary": "Iowa City, Iowa • Pittsburgh, Pennsylvania • Nashville, Tennessee", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03819465" } ] }